Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
Carregando...
Data
2014-03-01
Autores
Mello Ayres Putinatti, Maria Stella de [UNESP]
Lastoria, Joel Carlos [UNESP]
Padovani, Carlos Roberto [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Soc Brasileira Dermatologia
Resumo
BACKGROUND: Leprosy can have its course interrupted by type 1 and 2 reactional episodes, the last named of erythema nodosum leprosum (ENL). Thalidomide has been the medication of choice for the control of ENL episodes since 1965. OBJECTIVES: These episodes can repeat and cause damages to the patient. In order to prevent these episodes, an extra dose of 100 mg/day thalidomide was used during six months, followed by a follow-up period of six more months after thalidomide discontinuation. METHODS: We included 42 patients with multibacillary (MB) leprosy who had episodes of ENL. They were male and female patients aged between 18 and 84 years. RESULTS: Of the 42 patients, 39 (92.85%) had the lepromatous form and three (7.15%) had the borderline form. We found that 100% of patients had no reactional episode during the use of the drug. During the follow-up period after thalidomide discontinuation, 33 (78.57%) patients had no reactional episode and nine (21.43%), all of them with the lepromatous form, had mild episodes, which were controlled using non-steroidal anti-inflammatory. There were no thalidomide-related side effects. CONCLUSION: A maintenance dose of 100 mg/day of thalidomide showed to be effective to prevent repeated type 2 reactional episodes of ENL.
Descrição
Palavras-chave
Erythema nodosum, Leprosy, Medication therapy management, Thalidomide
Como citar
Anais Brasileiros De Dermatologia. Rio De Janeiro Rj: Soc Brasileira Dermatologia, v. 89, n. 2, p. 266-272, 2014.